Cjc-1295 No Dac Certificate Of Analysis

Understanding the CJC-1295 No DAC Certificate of Analysis

In biomedical and preclinical research, data integrity relies heavily on the quality and purity of test compounds. A CJC-1295 No DAC certificate of analysis serves as a comprehensive quality control report that verifies the exact chemical composition of a specific synthesized batch. Also known scientifically as Modified GRF 1-29, CJC-1295 without Drug Affinity Complex (DAC) is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH). Without a verified COA, researchers risk introducing unquantified impurities, TFA (trifluoroacetic acid) residues, or degraded peptide fragments into cell culture or animal models, which can skew experimental outcomes.

PX1 Research provides lot-specific certificates of analysis for every batch of CJC-1295 No DAC. Each document details third-party analytical testing results performed by independent analytical laboratories. By making these analytical metrics accessible prior to procurement, laboratory personnel can confirm that their test reagents meet strict criteria for purity, mass exactness, and low bioburden.

Essential Analytical Metrics Found on a CJC-1295 No DAC COA

A rigorous CJC-1295 No DAC certificate of analysis contains three core analytical testing sections: purity analysis via RP-HPLC, identity verification via ESI-MS, and safety/bioburden screening via Limulus Amebocyte Lysate (LAL) testing. Understanding how to read these metrics ensures that researchers receive compound batches suited for sensitive in vitro assays or preclinical animal trials.

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): HPLC isolates the primary peptide from synthesis truncated sequences, deletion peptides, and side-reaction products. A single, sharp peak on the HPLC chromatogram indicates a homogeneous compound. PX1 Research mandates that every batch of CJC-1295 No DAC achieves a minimum purity of 98.0%, with specific area percentages clearly listed on the COA.

2. Electrospray Ionization Mass Spectrometry (ESI-MS): While HPLC confirms purity, mass spectrometry verifies chemical identity by measuring the exact mass-to-charge ratio (m/z) of the peptide. The theoretical molecular weight of CJC-1295 No DAC (C152H252N44O42) is approximately 3367.2 Da. The MS spectrum on the COA must display a observed molecular weight matching this theoretical baseline within acceptable experimental tolerance.

3. Endotoxin Assay (LAL Test): Endotoxins are lipopolysaccharides (LPS) derived from Gram-negative bacterial cell walls that induce acute inflammatory cascades in biological models. A compliant COA provides endotoxin quantification expressed in Endotoxin Units per milligram (EU/mg), keeping levels strictly below established regulatory and operational thresholds for experimental use.

Biological Mechanism: GHRH Receptor Agonism in Preclinical Studies

CJC-1295 No DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R) located on pituitary somatotrophs. As a modified version of the naturally occurring 44-amino acid native GHRH, the 1-29 sequence represents the minimal functional fragment required for biological activity, augmented by strategic amino acid substitutions (such as D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27) that increase resistance to enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV).

When bound to the GHRH-R, CJC-1295 No DAC activates intracellular adenylate cyclase, raising cyclic adenosine monophosphate (cAMP) levels and triggering protein kinase A (PKA) signaling cascades. In laboratory models, this mechanism stimulates the physiological, pulsatile release of endogenous growth hormone (GH). Because it lacks the maleimidopropionic acid reactive linker present in DAC-bound variants, CJC-1295 No DAC exhibits a half-life of approximately 30 minutes in plasma, closely mimicking native physiological GHRH surges without causing continuous, non-pulsatile receptor saturation.

Preclinical Literature: GH and Downstream IGF-1 Dynamics in Tissue Repair

Preclinical studies evaluate CJC-1295 No DAC primarily for its ability to sustain elevated serum growth hormone and downstream insulin-like growth factor 1 (IGF-1) concentrations. In rodent and non-human primate research models, secretagogue-induced elevation of the GH/IGF-1 axis has been shown to enhance metabolic turnover, accelerate protein synthesis, and facilitate cellular regeneration across diverse biological tissues.

In vitro models investigating musculoskeletal and connective tissue repair demonstrate that pulsed GHRH receptor activation promotes fibroblast proliferation, collagen matrix deposition, and osteoblast differentiation. Furthermore, research literature highlights the synergetic potential of pairing GHRH analogs with selective growth hormone secretagogue receptor (GHSR) agonists. To review the complete range of research tools available for endocrine and metabolic investigations, explore our comprehensive all peptides catalog.

Comparative Analysis: CJC-1295 No DAC vs. CJC-1295 DAC vs. Sermorelin

When designing preclinical protocols, investigators must select the appropriate GHRH analog based on desired pharmacokinetics and receptor activation dynamics. A comparison between related compounds in this class helps clarify experimental applications:

CJC-1295 No DAC vs. CJC-1295 DAC: The addition of the Drug Affinity Complex (DAC) allows the peptide to covalently bind to circulating serum albumin, extending its biological half-life from ~30 minutes to several days. While CJC-1295 DAC causes sustained, continuous GH elevation, CJC-1295 No DAC provides controlled, episodic GH release that closely replicates endogenous physiological signaling.

CJC-1295 No DAC vs. Sermorelin: Sermorelin corresponds to the native GRF 1-29 sequence without chemical modifications. While Sermorelin acts through the exact same receptor, CJC-1295 No DAC includes four specific amino acid substitutions that markedly increase metabolic stability against DPP-IV enzymatic degradation. Additionally, researchers frequently combine GHRH secretagogues with ghrelin mimetics such as Ipamorelin to evaluate dual-receptor synergistic amplification of pituitary GH release.

Supplier Quality Verification, USA Manufacturing, and Lot Traceability

Acquiring high-purity peptides for academic, biotechnological, or pharmaceutical research requires rigorous vendor audit protocols. Substandard or unverified peptide compounds risk introducing uncharacterized experimental variables that compromise whole-study datasets.

At PX1 Research, all research compounds are USA-manufactured in ISO 17025-accredited and GMP-compliant production facilities. Every batch undergoes mandatory third-party COA verification, including high-resolution RP-HPLC chromatograms, mass spectrum charts, and LAL endotoxin testing data. Furthermore, every vial features clear lot traceability, allowing research teams to match their physical inventory directly to published laboratory verification records maintained in our central research hub.

Reconstitution Protocol and Laboratory Handling Guidelines

To maintain the structural stability of CJC-1295 No DAC following receipt, research staff must execute standardized reconstitution and handling protocols under sterile laminar flow conditions:

1. Reconstitution: Reconstitute lyophilized CJC-1295 No DAC powder using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile laboratory-grade saline. Direct the reconstituting solvent down the inner glass wall of the vial rather than shooting it directly onto the lyophilized cake.

2. Dissolution: Gently swirl the vial in a smooth circular motion until the cake dissolves completely into a clear, colorless liquid. Never shake or vortex peptide solutions, as mechanical shear stress can disrupt delicate secondary structures and promote peptide aggregation.

3. Aliquoting: To minimize repeated freeze-thaw cycles—which degrade peptide bonds—aliquot the reconstituted solution into single-use microcentrifuge tubes using sterile technique prior to initial experimental use.

Storage and Stability Specifications for Research Operations

Proper temperature control is critical to maintaining the chemical integrity of lyophilized and reconstituted CJC-1295 No DAC over extended experimental timelines:

Lyophilized Powder: Store sealed, desiccated vials at -20°C for medium-term storage (up to 24 months) or -80°C for long-term archival storage. Protect vials from direct light exposure.

Reconstituted Solution: Store reconstituted liquid aliquots at 2°C to 8°C (refrigerated) for immediate use over a 14-to-28-day window. For longer preservation, store aliquots at -20°C or -80°C. Avoid repeated freeze-thaw operations. For institutional procurement, research laboratories and academic institutions can establish direct fulfillment options through our dedicated wholesale accounts program.